Order Article Reprints

Dirks I, Keyaerts M, Dirven I, Neyns B, Vandemeulebroucke J. Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [¹⁸F]FDG PET/CT Imaging and Clinical Features. Cancers. 2023; 15(16):4083. https://doi.org/10.3390/cancers15164083

Dirks, Ine, Marleen Keyaerts, Iris Dirven, Bart Neyns, and Jef Vandemeulebroucke. 2023. "Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [¹⁸F]FDG PET/CT Imaging and Clinical Features" Cancers 15, no. 16: 4083. https://doi.org/10.3390/cancers15164083

Dirks, I., Keyaerts, M., Dirven, I., Neyns, B., & Vandemeulebroucke, J. (2023). Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [¹⁸F]FDG PET/CT Imaging and Clinical Features. Cancers, 15(16), 4083. https://doi.org/10.3390/cancers15164083